Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study.
Alessandro VitaleFabio FarinatiGiulia NoaroPatrizia BurraTimothy M PawlikLaura BucciEdoardo Giovanni GianniniChiara FaggianoFrancesca CiccareseGian Lodovico RapacciniMaria Di MarcoEugenio CaturelliMarco ZoliFranco BorzioRodolfo SaccoGiuseppe CabibboRoberto VirdoneFabio MarraMartina FelderFilomena MoriscoLuisa BenvegnùAntonio GasbarriniGianluca Svegliati-BaroniFrancesco Giuseppe FoschiAndrea OlivaniAlberto MasottoGerardo NardoneAntonio ColecchiaFabio FornariMassimo MarignaniSusanna VicariEmanuela BortoliniRaffaele CozzolongoAlessandro GrassoCamillo AlibertiMauro BernardiAnna Chiara FrigoMauro BorzioFranco TrevisaniUmberto Cillonull nullPublished in: Hepatology (Baltimore, Md.) (2019)
Although the ITA.LI.CA score demonstrated the best prognostic performance at restaging, other variables should be considered to improve the prognostic assessment of patients at the time of deciding additional therapies for HCC.